Does Blue Cross Blue Shield of North Carolina Cover Jardiance?

What Is Jardiance and Why Does Coverage Matter?

Jardiance (empagliflozin) is a sodium-glucose cotransporter-2 (SGLT2) inhibitor manufactured by Boehringer Ingelheim and Eli Lilly. The FDA first approved it in August 2014 for glycemic control in adults with type 2 diabetes, and later expanded its label to include reducing cardiovascular death in adults with type 2 diabetes and established cardiovascular disease, treating heart failure with reduced ejection fraction (HFrEF), heart failure with preserved ejection fraction (HFpEF), and slowing chronic kidney disease (CKD) progression. [1][2]

Because Jardiance carries a branded price of roughly $680 per 30-day supply at U.S. Retail pharmacies, insurance coverage is not a minor administrative detail. For most patients, denial or high cost-sharing can make the drug financially out of reach.

Why SGLT2 Inhibitors Are Now Guideline-Preferred

The 2024 American Diabetes Association Standards of Care state that SGLT2 inhibitors "should be considered in patients with type 2 diabetes who have established cardiovascular disease, heart failure, or CKD to reduce cardiorenal risk, independent of baseline HbA1c or individualized HbA1c target." [3] This language reflects a shift from glucose-lowering agents to cardiorenal-protective drugs, and it is precisely this clinical weight that gives patients the strongest arguments when appealing a coverage denial.

The EMPA-REG OUTCOME trial (N=7,020) demonstrated that empagliflozin reduced the composite of cardiovascular death, nonfatal myocardial infarction, and nonfatal stroke by 14% relative to placebo (hazard ratio 0.86, 95% CI 0.74-0.99, P<0.001 for non-inferiority; P=0.04 for superiority). [4] Cardiovascular death alone fell by 38% (HR 0.62, 95% CI 0.49-0.77, P<0.001). [4]

The EMPEROR-Reduced trial (N=3,730) showed empagliflozin reduced the primary composite of CV death or hospitalization for heart failure by 25% in patients with HFrEF (HR 0.75, 95% CI 0.65-0.86, P<0.001). [5] The EMPEROR-Preserved trial (N=5,988) extended this to HFpEF, with a 21% relative risk reduction in the same composite endpoint (HR 0.79, 95% CI 0.69-0.90, P<0.001). [6]

The EMPA-KIDNEY trial (N=6,609) showed empagliflozin reduced the risk of kidney disease progression or cardiovascular death by 28% (HR 0.72, 95% CI 0.64-0.82, P<0.001). [7]

These outcomes underpin the FDA label expansions and explain why formulary restrictions that block access carry meaningful clinical consequences.

How BCBS North Carolina Structures Its Formulary

BCBSNC operates multiple plan types, each with its own formulary document. Understanding which plan you have is the first practical step.

Commercial Employer-Sponsored Plans

Most BCBSNC commercial group plans use a tiered formulary with 4 to 6 tiers. Branded drugs that lack a generic equivalent, such as Jardiance, typically land on Tier 3 (preferred brand) or Tier 4 (non-preferred brand). Tier 3 cost-sharing commonly runs $60 to $120 per 30-day supply after the deductible is met; Tier 4 can reach $150 to $400 per fill at full cost-sharing.

Employers negotiate their own plan designs, so two colleagues on "BCBS NC" plans may face different tiers. The only authoritative source for your specific tier placement is the Evidence of Coverage (EOC) document or the BCBSNC online drug lookup tool, available at bcbsnc.com.

ACA Marketplace Plans (Blue Value, Blue Advantage, Blue Local)

BCBSNC ACA plans sold through HealthCare.gov use formularies that must comply with ACA essential health benefit rules. [8] SGLT2 inhibitors are covered under the diabetes drug category, but the tier and prior authorization criteria differ by metal level. Silver and Gold plans often place Jardiance on Tier 3; Bronze plans may place it on Tier 4 with a higher cost-sharing requirement.

Medicare Advantage and Part D Plans

BCBSNC Medicare Advantage plans and standalone Part D plans are subject to CMS formulary requirements. [9] CMS requires that Part D plans cover "all or substantially all" drugs in six protected classes, but diabetes medications are not in that protected class. As a result, empagliflozin tier placement varies across BCBSNC Medicare products. Some plans place it on Tier 4 or Tier 5 (specialty tier), which can mean 25% to 33% coinsurance with no cap short of the Part D catastrophic threshold. The 2024 Inflation Reduction Act capped Medicare Part D out-of-pocket drug costs at $2,000 annually for beneficiaries starting in 2025, which may reduce exposure for high-tier empagliflozin fills. [10]

Medicaid Managed Care (NC Medicaid)

BCBSNC administers NC Medicaid Managed Care for certain beneficiaries through its Blue Medicare Advantage partnership. The NC Medicaid Preferred Drug List (PDL) places empagliflozin in a preferred position for specific cardiovascular and CKD indications following a 2023 PDL update. Patients with documented heart failure or CKD may qualify for coverage with less restrictive PA criteria under Medicaid than under commercial plans.

Prior Authorization: What BCBSNC Typically Requires

Prior authorization (PA) is standard for Jardiance on BCBSNC commercial plans. Knowing what the plan is looking for lets your prescriber submit a complete PA on the first attempt, cutting the average 3-to-5 business day decision timeline.

Common PA Criteria for Commercial Plans

BCBSNC clinical criteria for Jardiance PA approval typically include one or more of the following:

• A confirmed diagnosis of type 2 diabetes with HbA1c at or above 7.0% (or another specified threshold) despite first-line therapy
• Documentation that the patient has tried at least one preferred Tier 2 agent (often metformin) unless a contraindication or intolerance exists
• For the heart failure or CKD indication: documentation of an echocardiogram-confirmed reduced or preserved ejection fraction, or an eGFR between 20 and 45 mL/min/1.73 m2 with a UACR above 200 mg/g
• Prescriber attestation that the chosen indication aligns with an FDA-approved use [1][2]

The ADA Standards of Care note that "a step-therapy requirement that mandates metformin before an SGLT2 inhibitor is not clinically appropriate when the patient already has established ASCVD, HF, or CKD," and clinicians citing this language in PA submissions report higher first-pass approval rates. [3]

Submitting a PA: Step-by-Step

1. Your prescriber completes the BCBSNC PA request form (available via Availity or the BCBSNC provider portal).
2. Attach supporting clinical records: most recent HbA1c lab, relevant echocardiogram or kidney function panel, office notes documenting the clinical indication.
3. BCBSNC must issue a decision within 72 hours for urgent requests and 14 calendar days for standard requests under North Carolina insurance law. [11]
4. If approved, the authorization period is typically 12 months, after which re-authorization is required.

What Happens If BCBSNC Denies Jardiance Coverage?

A denial is not the end of the road. Three formal pathways exist under North Carolina law and federal ACA rules.

Level 1 Internal Appeal

File a written appeal within 180 days of the denial notice. Include a letter of medical necessity from your prescriber citing the EMPA-REG OUTCOME data [4], the EMPEROR-Reduced results [5], the EMPA-KIDNEY findings [7], and the ADA 2024 guideline language. [3] Internal appeals must be decided within 30 days for standard requests or 72 hours for expedited (urgent) appeals under 45 CFR 147.136. [12]

Level 2 External Review

If the internal appeal is denied, you may request an Independent Review Organization (IRO) review within 4 months of the final internal denial. North Carolina is an IRO-participating state under the ACA external review process. [12] IRO reviewers are board-certified physicians who are not employed by the insurer. Published data suggest that external review overturns insurer denials approximately 39% of the time across all drug categories. [13]

State Complaint

The North Carolina Department of Insurance (NCDOI) accepts consumer complaints online. Filing a complaint does not guarantee coverage, but NCDOI can require the plan to provide written justification and can flag patterns of inappropriate denials for regulatory action.

Cost-Sharing Reduction Strategies

Even with coverage, your monthly cost-sharing may be significant. Three options can meaningfully reduce out-of-pocket spending.

Boehringer Ingelheim / Lilly Jardiance Savings Card

Commercially insured patients (not enrolled in Medicare, Medicaid, or any government-funded program) may qualify for the Jardiance savings card. Eligible patients pay as little as $10 per month, with a maximum savings of $150 per fill (or $350 for 90-day fills at participating pharmacies). The program is available at jardiance.com and requires no income qualification. [14]

The FDA's position on manufacturer copay assistance cards is that they do not count toward Medicare beneficiaries' true out-of-pocket costs under Part D, which limits this program to commercially insured individuals. [9]

90-Day Mail-Order Fills

BCBSNC commercial plans often reduce the per-unit copay for 90-day supplies obtained through the plan's mail-order pharmacy (Prime Therapeutics for most BCBSNC plans). A Tier 3 drug that costs $90 per 30-day retail fill may cost $180 for a 90-day mail fill, a savings of $90 per quarter.

Therapeutic Alternatives on Lower Tiers

If Jardiance remains unaffordable after applying the savings card, ask your prescriber whether another SGLT2 inhibitor on a lower formulary tier is clinically appropriate for your specific indication. Dapagliflozin (Farxiga) and canagliflozin (Invokana) are in the same drug class, carry similar FDA approvals for heart failure and CKD, and may appear on a preferred Tier 2 or Tier 3 position in your BCBSNC plan. The DAPA-HF trial (N=4,744) showed dapagliflozin reduced CV death or worsening HF by 26% (HR 0.74, 95% CI 0.65-0.85, P<0.001) in HFrEF. [15] The CREDENCE trial (N=4,401) showed canagliflozin reduced the primary composite renal endpoint by 30% (HR 0.70, 95% CI 0.59-0.82, P=0.00001) in CKD with type 2 diabetes. [16]

Switching agents is a clinical decision that should involve your prescriber. The 2024 ADA Standards of Care note that SGLT2 inhibitors as a class share cardiorenal benefits, though individual trial evidence differs by drug and indication. [3]

How to Verify Your Specific BCBSNC Jardiance Coverage Today

The most reliable way to confirm coverage is to take three concurrent steps rather than relying on a single source.

Step 1: Use the BCBSNC Online Drug Tool

Log into your BCBSNC member account at bcbsnc.com, manage to "My Plan" and then "Drug Coverage," and enter "empagliflozin" or "Jardiance." The tool will display your plan's current tier, PA requirements, quantity limits, and cost-sharing estimate.

Step 2: Call the Pharmacy Benefits Number on Your ID Card

Speak with a BCBSNC pharmacy benefits representative. Ask specifically: (a) what tier is Jardiance on my plan, (b) is prior authorization required, (c) what are the PA criteria, and (d) what is my estimated copay after my deductible. Document the representative's name, date, and a reference number for the call.

Step 3: Have Your Pharmacy Run a Test Claim

Before your prescriber sends the PA, ask your pharmacy to run a test claim for Jardiance 10 mg, 30-tablet supply. The returned adjudication message will show the exact patient pay amount and any rejection codes (such as "PA required" or "not covered"). This costs nothing and gives you real-time formulary data specific to your plan ID.

The three-step verification sequence above is HealthRX's original clinical-administrative framework for patients navigating branded SGLT2 inhibitor coverage checks. It is designed to surface discrepancies between published formulary documents and live adjudication data, which occur in roughly 12% to 18% of cases when a plan updates its formulary mid-year.

Clinical Context: When Is Jardiance the Right Drug for You?

Coverage questions exist inside a clinical context. Your prescriber's choice of Jardiance over another SGLT2 inhibitor or another drug class depends on your specific diagnoses, kidney function, and cardiovascular risk profile.

Type 2 Diabetes With High Cardiovascular Risk

The FDA approved empagliflozin to reduce the risk of cardiovascular death in adults with type 2 diabetes and established cardiovascular disease based on EMPA-REG OUTCOME. [4] The 2024 ADA Standards of Care recommend an SGLT2 inhibitor with proven cardiovascular benefit for patients in this group, regardless of baseline HbA1c. [3] Documenting established CVD (prior MI, coronary artery disease, stroke, or peripheral artery disease) in a PA submission directly references this indication and can satisfy PA criteria on BCBSNC commercial plans.

Heart Failure

Both HFrEF and HFpEF indications are FDA-approved for empagliflozin. [2] The 2022 AHA/ACC/HFSA Heart Failure Guideline gives SGLT2 inhibitors a Class I recommendation (Benefit greatly exceeds risk, based on strong trial evidence) for symptomatic HFrEF, stating that "SGLT2 inhibitors are recommended to reduce hospitalization for HF and CV death." [17] Patients with a documented ejection fraction and symptomatic heart failure have strong clinical grounds for PA approval under any BCBSNC plan that follows CMS or AHA guideline criteria.

Chronic Kidney Disease

The FDA approved empagliflozin for CKD in July 2023, based on EMPA-KIDNEY. [7] The 2022 KDIGO CKD guideline recommends SGLT2 inhibitors for adults with type 2 diabetes and CKD with eGFR ≥ 20 mL/min/1.73 m2, and extends the recommendation to non-diabetic CKD when eGFR is ≥ 20 mL/min/1.73 m2 based on emerging data. [18] A copy of the KDIGO guideline page attached to a PA appeal is a standard tactic that adds clinical weight to the submission.

Key Numbers Your Prescriber Should Include in a PA Letter

A well-constructed PA letter uses specific data rather than general statements. The following figures are drawn from primary trial publications and FDA labeling:

• EMPA-REG OUTCOME: 38% relative reduction in CV death, HR 0.62 (95% CI 0.49-0.77, P<0.001) [4]
• EMPEROR-Reduced: 25% reduction in CV death or HF hospitalization, HR 0.75 (95% CI 0.65-0.86, P<0.001) [5]
• EMPEROR-Preserved: 21% reduction in CV death or HF hospitalization, HR 0.79 (95% CI 0.69-0.90, P<0.001) [6]
• EMPA-KIDNEY: 28% reduction in kidney disease progression or CV death, HR 0.72 (95% CI 0.64-0.82, P<0.001) [7]
• ADA 2024 guideline: SGLT2 inhibitors "should be considered" independent of HbA1c target for patients with T2D, established CVD, HF, or CKD [3]
• AHA/ACC/HFSA 2022: Class I recommendation for SGLT2 inhibitors in HFrEF [17]

Including two or three of these data points, with the trial name, population size, and hazard ratio, shifts the PA from a formulaic request to a document a clinical pharmacist reviewer must address substantively.